# The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma

> **NCT04356872** · PHASE2 · UNKNOWN · sponsor: **Fudan University** · enrollment: 45 (estimated)

## Conditions studied

- Sarcoma, Soft Tissue

## Interventions

- **DRUG:** Sintilimab
- **DRUG:** Doxorubicin Hydrochloride
- **DRUG:** Ifosfamide

## Key facts

- **NCT ID:** NCT04356872
- **Lead sponsor:** Fudan University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2020-04-08
- **Primary completion:** 2022-03-30
- **Final completion:** 2023-03-30
- **Target enrollment:** 45 (ESTIMATED)
- **Last updated:** 2020-07-14

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04356872

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04356872, "The Combination of Sintilimab and AI (Doxorubicin, ADM/Ifosfamide, IFO) for the First Line Treatment of Select Type of Metastatic/Unresectable Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT04356872. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*